Mirum Pharmaceuticals, Inc.
NASDAQ:MIRMBiotechnology
+$3.89 today
- Market cap
- $6.04B
- Beta
- 0.51
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$13.57
Volume 0.50M
Average 0.95M
MIRM Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Mirum Pharmaceuticals, Inc.NASDAQ: MIRM
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $66.78M rose 261.6% year over year, ahead of the +135.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 84.5% from the prior quarter. Over 3 fiscal years it compounded at +38.3% a year.
Context
- Stock-based compensation amounted to 13.7% of revenue in FY2025, down 0.7 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +261.6% holds above the trailing-twelve-month pace of +135.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 71.42M USD
- Year-over-year change
- +47.4%
- 4-year CAGR
- +32.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71.42M | +47.4% |
| FY2024 | 2024-12-31 | 48.44M | +38.3% |
| FY2023 | 2023-12-31 | 35.02M | +29.7% |
| FY2022 | 2022-12-31 | 27.01M | +17.0% |
| FY2021 | 2021-12-31 | 23.09M | — |
Stock-Based Compensation vs competitors
How MIRM compares with its peers on the latest reported figures
- MIRM's LTM Jun 2026 stock-based compensation of $140.13M is the 2nd largest of the 8 companies compared; the peer median is $56.73M.
- Its year-over-year change of +135.8% is the highest of 8, against a peer median of +4.6%.
- Stock-based compensation amounts to 22.7% of revenue for MIRM, versus a peer median of 22.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $142.83M | -11.3% | +5.5% | 21.3% | |
| LTM Jun 2026 | $140.13M | +135.8% | +38.3% | 22.7% | |
| LTM Jun 2026 | $95.64M | +17.1% | +45.9% | 7.4% | |
| LTM Sep 2026 | $72.84M | +70.9% | +5.6% | 11.2% | |
| LTM Mar 2026 | $56.73M | +26.2% | +2.2% | 85.9% | |
| LTM Mar 2026 | $23.07M | -33.2% | -6.0% | 50.9% | |
| LTM Mar 2026 | $15.77M | -32.9% | -11.7% | 22.8% | |
| LTM Mar 2026 | $15.44M | +4.6% | +25.7% | 42886.1% | |
| Peer median (excluding MIRM) | $56.73M | +4.6% | +5.5% | 22.8% | |
Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (83.99M) | (135.67M) | (163.42M) | (87.94M) | (23.36M) |
| Depreciation & Amortization | 975K | 3.24M | 10.83M | 23.63M | 24.24M |
| Deferred Income Tax | 595K | (6.58M) | 0 | 0 | 0 |
| Stock-Based Compensation | 23.09M | 27.01M | 35.02M | 48.44M | 71.42M |
| Change in Working Capital | 16.98M | (21.05M) | (22.64M) | 22.59M | (19.72M) |
| Accounts Receivables | 0 | (20.73M) | (43.97M) | (11.43M) | (48.06M) |
| Inventory | (495K) | (3.45M) | (4.39M) | (3.17M) | (8.45M) |
| Accounts Payables | 22.66M | 7.64M | 30.78M | 40.31M | 50.1M |
| Other Working Capital | (5.18M) | (4.51M) | (5.05M) | (3.13M) | (13.32M) |
| Other Non-Cash Items | (90.41M) | 12.91M | 69.26M | 3.6M | 3.24M |
| Operating Cash Flow | (132.76M) | (120.14M) | (70.94M) | 10.33M | 55.83M |
| Capital Expenditures | (19.02M) | (278K) | (20.11M) | (993K) | (954K) |
| Acquisitions (Net) | (19M) | (7.98M) | (212.76M) | 0 | 0 |
| Purchases of Investments | (198.03M) | (132.32M) | (27.33M) | (89.03M) | (97.43M) |
| Sales of Investments | 157.6M | 140.3M | 153M | 19.89M | 74.43M |
| Other Investing Activities | 127M | 7.98M | (20M) | (20M) | 0 |
| Investing Cash Flow | 48.55M | 7.7M | (107.2M) | (90.13M) | (23.95M) |
| Debt Repayment | 0 | 0 | 305.3M | 0 | 0 |
| Common Stock Issued | 6.91M | 107.37M | 216.68M | 17.7M | 40.14M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 66.55M | 1.72M | (185.39M) | 0 | 0 |
| Financing Cash Flow | 73.47M | 109.09M | 336.6M | 17.7M | 40.14M |
| Effect of Forex Changes | (1K) | 12K | (133K) | (1.3M) | 3.22M |
| Net Change in Cash | (10.75M) | (3.34M) | 158.32M | (63.4M) | 75.24M |
| Free Cash Flow | (151.78M) | (120.41M) | (91.05M) | 9.33M | 54.87M |
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
Intrinsic Alpha fair value
Locked
Current Price
$92.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.